Mohanad Nada

Associate Professor of Pathology/Hematology, (MHS) Department Chair
Department of Medical & Health Sciences (MHS)
  • Postdoctoral Fellowship University of Iowa Hospital & Clinics UIHC 
    Ph.D. University of Iowa Carver College of Medicine
    C.P.H. University of Iowa Colelge of Public Health
    M.Sc. Tikrit University
  • Email: [email protected]
  • Office: B-F2-17

Profile

Dr. Mohanad Nada, or Dr. Mo as he likes to be called, is a medical specialist in immunopathology. He has completed extensive training and research in the field of Onco-immunology and pathology in the U.S. and other countries. He obtained his Ph.D. from Carver College of Medicine at the University of Iowa along with a Graduate Diploma in Public Health with special focus on cancer prevention. Before joining AUIS, Dr. Mo worked as a postdoctoral fellow in the Department of Internal Medicine at the University of Iowa Hospital and Clinics UIHC. He has more than six years of active academic teaching experience in American and Iraqi medical schools. Dr. Mo has recently gained the full membership in the European Society of Medical Oncology (ESMO). Also, he was selected as an Obermann Graduate Institute for Advance Studies fellow. Dr. Mo is an active member of several professional organizations, including the American Association of Cancer Research (AACR), American Association of Immunologists (AAI), and the Society of Immunotherapy for Cancer (SITC). 

Dr. Mo is an active medical researcher through collaborations with medical researchers in the U.S. and Europe. His research focuses on tumor immunology and immunotherapy, aiming to develop new approaches to cure cancer using the body's own immune system. His research has been published in high-impact journals in the U.S. and Europe. In 2019, Dr. Mo won the Munich Cancer Center Award for best-presented paper in the ITOC 06 conference in Vienna. One of his papers has been published in JITC with an impact factor of 8.40.

Dr. Mo is open for collaborations with other physicians and researchers who are interested in his field. 

Google Scholar Profile


 

Publications

  • Nada MH and Morita CT. PD-1 checkpoint blockade enhances the adoptive immunotherapy of human Vγ2Vδ2 T cells against human prostate cancer. (Manuscript being submitted)
  • Wang H, Nada MH, Tanaka Y, Sakuraba Y, Morita CT. Critical Roles for Coiled-Coil Dimers of Butyrophilin 3A1 in the Sensing of Prenyl Pyrophosphates by Human Vγ2Vδ2 T Cells The Journal of Immunology, 2019
  • Nada MH, Wang H, Workalemahu G, Morita CT. Enhancing Adoptive Cancer Immunotherapy with Vγ2Vδ2 T Cells through Pulse Zoledronate Stimulation. Journal for ImmunoTherapy of Cancer 5.1 (2017):9. https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0209-6
  • Tanaka Y, Murata K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Science. 2017 Dec. https://www.onlinelibrary.wiley.com/doi/full/10.1111/cas.13491
  • Workalemahu G, Wang H, Nada MH, Puan K-J, Kuzuyama T, Jones BD, Jin C, Morita CT. Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity. Journal of Immunology 2014; 193:708.
  • Nada, MH. Prognostic value of IL-6 in breast cancer patients. TMJ 2010;17-23